Skip to content
value.today
Advaxis Inc. logo

Advaxis Inc.

ADXSUnlisted company
$6 Mlast known market cap, Jul 2023 — no current value
Compare
World rank
—
no current market cap
Revenue
$0 M
For year ending December-2023
Net income
$-48 M
-480700.0% margin
SEC filing
Employees
—

Advaxis Inc. in brief

Advaxis Inc. is an unlisted company in the Biotechnology industry, based in Monmouth Junction, New Jersey, USA. It was founded in 2002. In the year to December 2023 it had sales of $0 M and a net loss of $48 M.

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Advaxis Inc.

Advaxis Immunotherapies Inc. was an American company that focused on the discovery, development, and commercialization of immunotherapies based on a genetically engineered platform based on Listeria monocytogenes (aka Lm). The company merged with Ayala Pharmaceuticals, with the newly formed company beginning operations under the name Ayala Pharmaceuticals in January 2023.

The Lm-based platform on which the company's products were based involves the use of an attenuated Lm, which secretes an antigen/adjuvant fusion protein and stimulates a patient's immune system (specifically their T cells) to mount an immune response to the secreted antigen. If the antigen is specifically found on cancerous cells, the result is an immune response targeting and eliminating the cancer. Treatments developed using this paradigm are referred to as Lm-LLO immunotherapies.

The company had over fifteen constructs in various stages of development, both directly and through strategic collaborations with centers, such as the National Cancer Institute, Cancer Research UK, the Wistar Institute, the University of Pennsylvania, and the Department of Homeland Security,among others. The company also had a veterinary medicine program that was evaluating an Lm-LLO-based immunotherapy in a Phase 1 study in canine osteosarcoma.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Advaxis Inc. timeline

4 events, 1999–2023
  1. 1999
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2002
  4. 🏁
    · approximate
    Founded
  5. 2005
  6. ✎
    Renamed Advaxis, Inc.
    Formerly Great Expectations & Associates Inc.
  7. 2023
  8. ✎
    Renamed Ayala Pharmaceuticals, Inc.
    Formerly Advaxis, Inc..

Events of Advaxis Inc. from SEC EDGAR and Wikidata. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

More about Advaxis Inc.

Acquisitions and changes
Delisted: it ended its SEC registration (Form 15) on 9 May 2024.

Market cap history

$0 M$6 M$13 M$19 M$26 M2023

World rank over time

▼ down 2,517 places since 2022
2022-01-07: #30332#30,33220222022-12-25: #33775#33,77520222023-07-30: #32849#32,8492023

Rank in USA: #5,301 (Jan 2022) · #5,891 (Dec 2022) · #5,575 (Jul 2023)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
—
Price / book
—
Free cash flow yield
—
Net margin (TTM)
-480700.0%
Operating margin
-362700.0%
Return on equity
—
Liabilities / assets
247.3%
Revenue growth
-98.6%
R&D / revenue
240800.0%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Oct 2016: revenue $4M, net income $-74M$4MFY16Fiscal year ending Oct 2017: revenue $12M, net income $-93M$12MFY17Fiscal year ending Oct 2018: revenue $6M, net income $-67M$6MFY18Fiscal year ending Oct 2019: revenue $21M, net income $-17M$21MFY19Fiscal year ending Oct 2020: revenue $0M, net income $-26M$0MFY20Fiscal year ending Oct 2021: revenue $3M, net income $-18M$3MFY21Fiscal year ending Dec 2022: revenue $1M, net income $-38M$1MFY22Fiscal year ending Dec 2023: revenue $0M, net income $-48M$0MFY23
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2023$0M-98.6%$-36M$-48M-480700.0%
Dec 2022$1M-78.7%$-38M$-38M-5508.7%
Oct 2021$3M+1196.0%$-19M$-18M-551.2%
Oct 2020$0M-98.8%$-26M$-26M-10588.0%
Oct 2019$21M+244.6%$-18M$-17M-79.5%
Oct 2018$6M-49.6%$-70M$-67M-1097.7%
Oct 2017$12M+201.5%$-98M$-93M-776.7%
Oct 2016$4M—$-76M$-74M-1843.6%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2023$-29M——$-7.99—
Dec 2022$-35M——$-13.13—
Oct 2021$-15M——$-0.14—
Oct 2020$-22M——$-0.43—
Oct 2019$-36M$0M$-36M$-1.09—
Oct 2018$-62M$1M$-64M$-19.36—
Oct 2017$-77M$3M$-80M$-2.31—
Oct 2016$-9M$3M$-12M$-2.08—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$0M
Net income, trailing 12 months
$-48M
RevenueNet income
Three months to Mar 2023: revenue —, net income $-7M—Mar ’23Three months to Jun 2023: revenue $0M, net income $-9M$0MJun ’23Three months to Sep 2023: revenue —, net income $-7M—Sep ’23Three months to Dec 2023 (from the annual report): revenue —, net income $-25M—Dec ’23

Latest quarter to Dec 2023: revenue —, net income $-25M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Dec 2023.

SEC filings

Official filings of Advaxis Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$0 M
Operating income
$-36 M
Net income
$-48 M

For year ending December-2023 · source: SEC filing

Balance sheet

Total assets
$17 M
Total liabilities
$41 M
Total equity
$-24 M

As of December-2023

Insider trading at Advaxis Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
25
since
Advaxis Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Israel Biotech Fund GP Partners, L.P.Director, 10% ownerOption exerciseindirect+1.93 M$0.400$770 K11.04 MForm 4
filed Israel Biotech Fund GP Partners, L.P.Director, 10% ownerOption exerciseindirect+4.24 M$0.400$1.7 M18.36 MForm 4
filed Israel Biotech Fund GP Partners, L.P.Director, 10% ownerOption exerciseindirect+3.89 M$0.400$1.6 M14.93 MForm 4
filed Israel Biotech Fund GP Partners, L.P.Director, 10% ownerOption exerciseindirect+1.30 M$0.400$518 K19.66 MForm 4
filed Israel Biotech Fund GP Partners, L.P.Director, 10% ownerOption exerciseindirect+8.44 M$0.400$3.4 M23.37 MForm 4
filed Israel Biotech Fund GP Partners, L.P.Director, 10% ownerShares withheld for taxindirect-2.71 M$1.250$3.4 M20.66 MForm 4
filed Israel Biotech Fund GP Partners, L.P.Director, 10% ownerOption exerciseindirect+8.06 M$0.400$3.2 M27.72 MForm 4
filed Israel Biotech Fund GP Partners, L.P.Director, 10% ownerShares withheld for taxindirect-2.59 M$1.250$3.2 M25.13 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Advaxis Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-01-30
23
1 days to cover
Shares sold short, last 24 reportsAll stocks →

Fails to deliver

  • : 5 shares at $0.03
  • : 5 shares at $0.03
  • : 5 shares at $0.04
  • : 44 shares at $0.03
  • : 44 shares at $0.03

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Advaxis Inc. scorecard#

Passes 1 of the 8 checks that could be worked out. Fiscal year 2023.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth1 of 3
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-7.99 vs -13.13Diluted EPS -7.99 in fiscal 2023 against -13.13 the year before (report's currency).
    • ✓Net income higher than five years earlier-$48 M-$48 M in fiscal 2023 against -$67 M in 2018.
    • ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2023.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$48 MNet income -$48 M in fiscal 2023.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2023.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health0 of 2
    • ✗Short-term assets cover short-term liabilities0.3×Current ratio 0.30 at the end of fiscal 2023.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2023.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year107.9%Diluted shares up 107.9% in fiscal 2023.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Advaxis Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Advaxis Inc.: statements by fiscal year
PeriodTrendFY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Oct 31, 2021FY 2020to Oct 31, 2020FY 2019to Oct 31, 2019FY 2018to Oct 31, 2018FY 2017to Oct 31, 2017FY 2016to Oct 31, 2016FY 2015to Oct 31, 2015FY 2014to Oct 31, 2014
Income statement
Revenue0.00.73.20.3216.112r4.0—1.0
Cost of revenue0.00.6————————
Gross profit—0.1————————
Research and development24281116275771r4924r8.9r
General and administrative129.71111121940r3224r12r
Operating expenses——22273976110r8049r21
Operating income−36−38−19−26−18−70−98r−76−49r−20
Interest expense and finance costs—————————0.0
Other non-operating income (expense)−160.1−0.0—−0.0−0.1−0.1r−0.0−0.0r0.0r
Income before tax−52−37−18−26−17−66−98r−76−49−19
Income tax−3.90.60.10.10.10.1−4.4r−2.5−1.6−2.4
Net income attributable to shareholders−48−38−18−26−17−67−93r−74−47−17
Earnings per share, basic-7.99-13.13-11.07r-0.43-1.09-19.36r-2.31-2.08-1.68-0.97
Earnings per share, diluted-7.99-13.13-0.14-0.43-1.09-19.36r-2.31-2.08-1.68-0.97
Shares, weighted average (basic)6.02.91.6———————
Shares, weighted average (diluted)6.02.912961153.4r41352817
Balance sheet
Cash and cash equivalents4.92.44225324424r113r6718
Short-term investments—0.1————46r———
Receivables—0.2———1.7————
Other current assets0.20.0r1.60.91.41.6r2.9r0.1r0.00.0
Current assets7.53.24328365081r16011520
Property, plant and equipment0.51.00.12.44.46.77.1r4.41.10.1
Right-of-use (leased) assets0.11.50.04.85.3—————
Goodwill4.5—————————
Other intangible assets3.9—3.43.34.64.84.9r4.33.42.8
Non-current assets9.14.6————————
Total assets177.84739456294r16912023
Accounts payable6.14.10.10.41.05.65.1r1.70.71.4
Current liabilities256.2r7.93.34.52321r283.92.7
Lease liabilities (non-current)0.01.30.05.1——————
Non-current liabilities162.7r————————
Total liabilities——7.98.35.73839r504.02.7
Retained earnings−197−149−429−411−384−368−301r−208−134−87
Shareholders' equity−24−1.13930402454r119r11621
Total liabilities and equity177.84739456294r16912023
Shares outstanding122.6r1.8r78504.6r4140r3420
Cash-flow statement
Depreciation and amortization0.40.2———————0.2
Share-based compensation1.22.20.60.92.07.028r23215.4r
Cash from operating activities−29−35−15−22−36−62−77r−9.1r−24r−16r
Capital expenditure————−0.1−1.4−3.4r−3.2−1.0−0.0
Intangible assets bought——−0.5−0.7−1.2−1.4−1.2r−1.2−0.8−0.4
Cash from investing activities5.9−0.0−0.0−0.7−1.244r−12r1.6−47−0.4
Shares issued—0.5281524390.75312015
Cash from financing activities26−0.1321625390.4r54r121r14r
Exchange-rate effect on cash0.0—————————
Change in cash2.5−3516−7.2−1321————
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2023. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Advaxis Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Delisting notice 1 · Auditor changed 1 · Acquisition or sale completed 3 · Directors and officers 7 · Material agreement 6 · New debt 1 · Unregistered share sale 5 · Shareholder rights changed 1 · Bylaws or fiscal year changed 4 · Shareholder vote 5

Advaxis Inc.: events reported to the SEC
FiledWhat happenedFiling
Directors and officers8-K
Acquisition or sale completedUnregistered share sale8-K
Material agreementNew debt8-K
Directors and officers8-K
Unregistered share saleShareholder vote8-K
Directors and officersMaterial agreement8-K
Acquisition or sale completedDirectors and officersUnregistered share sale8-K
Material agreementUnregistered share sale8-K
Material agreementShareholder vote8-K
Auditor changed8-K
Bylaws or fiscal year changed8-K
Acquisition or sale completedDirectors and officersBylaws or fiscal year changed8-K
Shareholder vote8-K
Material agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changed8-K
Material agreement8-K
Directors and officersShareholder vote8-K
Bylaws or fiscal year changed8-K
Delisting notice8-K
Directors and officers8-K
Shareholder vote8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Apr 3, 2024

Acquisitions and funding#

8 private funding rounds before listing

Private share sales · funding history

Private share sales of Advaxis Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2022$5 MNo. 8$2 to $10 million6equitySEC
Apr 2021$11 MNo. 7$10 to $50 million2optionsSEC
May 2012$4 MNo. 6$2 to $10 million29equity, optionsSEC
Jan 2012$1 MNo. 5Under $2 million12debt, optionsSEC
Oct 2011$2 MNo. 4Under $2 million12debt, optionsSEC
May 2011$6 MNo. 3$2 to $10 million24debt, optionsSEC
Jul 2010$8 MNo. 2$2 to $10 million1equity, optionsSEC
Sep 2009$5 MNo. 1$2 to $10 million1optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Advaxis Inc. compares in Biotechnology

  • Revenue$0 M · higher than 13% of 647
  • Revenue growth-98.5% · higher than 1% of 438

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Advaxis Inc.🇺🇸$6 M——-98.5%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jul 30, 2023 (last known)
Annual results:
For year ending December-2023
Balance sheet:
As of December-2023
Profile updated:
Nov 16, 2026

Figures from SEC filing, Wikidata, value.today research, Wikipedia, Wikimedia Commons; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Advaxis Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Advaxis Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Advaxis Inc.? Suggest a correction